Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.

Takuji OkusakaKenji IkedaMasatoshi KudoRichard FinnShukui QinKwang-Hyub HanAnn-Lii ChengFabio PiscagliaMasahiro KobayashiMax SungMinshan ChenLucjan WyrwiczJung-Hwan YoonZhenggang RenKalgi ModyCorina DutcusToshiyuki TamaiMin RenSeiichi HayatoHiromitsu Kumada

Published in: Journal of gastroenterology (2021)

Trial registration ID: ClinicalTrials.gov # NCT01761266.

Keyphrases

body weight
phase iii
study protocol
phase ii
clinical trial
locally advanced
liver metastases
open label
squamous cell carcinoma